European Case Law Identifier: | ECLI:EP:BA:2013:T216508.20130306 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 06 March 2013 | ||||||||
Case number: | T 2165/08 | ||||||||
Application number: | 98942516.0 | ||||||||
IPC class: | C07H 21/00 | ||||||||
Language of proceedings: | EN | ||||||||
Distribution: | C | ||||||||
Download and more information: |
|
||||||||
Title of application: | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues | ||||||||
Applicant name: | Exiqon A/S | ||||||||
Opponent name: | Isis Pharmaceuticals, Inc. | ||||||||
Board: | 3.3.04 | ||||||||
Headnote: | - | ||||||||
Relevant legal provisions: |
|
||||||||
Keywords: | Main request - inventive step (no) Auxiliary request 1 and 2 - not admitted Auxiliary request 3 - added matter (no), novelty (yes), inventive step (yes) |
||||||||
Catchwords: |
- |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t082165eu1.html
Date retrieved: 17 May 2021